News

Experts Recommend Against Serum PCT as Biomarker in Ph-Negative MPNs

03/29/2021

Study findings lead experts to recommend against the use of serum procalcitonin (PCT) as a disease biomarker in patients with MPNs.

Study findings lead experts to...

03/29/2021

Oncology

Conference Insider

Naveen Pemmaraju, MD, Provides an Overview of Novel Therapies for MPNs

03/01/2021

During the virtual Great Debates & Updates in Hematologic Malignancies, Dr Pemmaraju discussed new therapies for myeloproliferative neoplasms (MPNs) with a focus on CMML.

During the virtual Great Debates...

03/01/2021

Oncology

News

Azacitidine–Eprenetapopt Combo Yields Responses in Patients With TP53-Mutant MDS

01/29/2021

Study findings suggest that eprenetapopt plus azacitidine is well-tolerated and leads to high rates of response and remission in patients with TP53-mutant MDS and oligoblastic AML.

Study findings suggest that...

01/29/2021

Oncology

News

Serum Ferritin Level Tied to Fibrosis in Older Patients With MF

01/28/2021

Researchers have observed a significant link between serum ferritin level and fibrosis in older patients with MF.

Researchers have observed a...

01/28/2021

Oncology

News

Pevonedistat Added to Azacitidine Promising for Higher-Risk MDS

01/12/2021

Pevonedistat plus azacitidine yields comparable safety to azacitidine monotherapy and demonstrates improvements in OS, EFS, and response rates in patients with higher-risk MDS.

Pevonedistat plus azacitidine...

01/12/2021

Oncology

News

Guadecitabine Maintenance Therapy Shows Promise in High Risk MDS/AML Patients

01/01/2021

Guadecitabine, when given as maintenance therapy following allo-SCT, showed promising relapse-free survival rates with manageable safety in high-risk MDS/AML patients.

Guadecitabine, when given as...

01/01/2021

Oncology

News

Ruxolitinib Plus Azacitidine Tolerable for Advanced Phase MPN, Post-MPN AML

12/02/2020

Ruxolitinib combined with azacitidine was a well-tolerated therapy option for patients with advanced phase MPN and post-MPN AML.

Ruxolitinib combined with...

12/02/2020

Oncology

News

Rigosertib-Azacitidine Combo Shows Promise in Patients With MDS, AML

10/14/2020

A combo therapy regimen of rigosertib and azacitidine yielded an overall response rate of >50% in patients with MDS, CMML, and AML.

A combo therapy regimen of...

10/14/2020

Oncology

News

Second Cancers a Cause of Death for Patients With Ph-Negative MPN

09/01/2020

Study findings suggest that second cancers are a relevant cause of death opposing MPN evolution in patients with Philadelphia-negative MPN.

Study findings suggest that...

09/01/2020

Oncology

News

FDA Approves Oral Decitabine–Cedazuridine Combo for Adults With MDS

07/07/2020

The FDA has approved an oral combination of decitabine and cedazuridine for the treatment of adults with MDS.

The FDA has approved an oral...

07/07/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology